Objective To observe the effect of Ginkgolide B of various consistency on the differentiation of neuron stem cells (NSCs).MethodsNSCs were cultured in differentiation medium containing Ginkgolide B of various consistency for 3 and 7 days, the neurites length and cell body area were measured by inverted phase-contrast micrograph, then neurofilament-200 (NF-200), glial fibrillary acidic protein (GFAP), adenomatus polyposis coli (CC-1) expression were detected and counted by fluorescence microscope. The suppressor of cytokine signaling-2 (SOCS2), inhibitor of DNA binding-2 (Id2) were alsoimmunostained. The percentage of positive cells were counted respectively.ResultsThe neurites length and cell body area in Ginkgolide B groups were obviously larger than that in the control group. The percentage of NF, GFAP positive cells in Ginkgolide B groups increased with dosage increasing of Ginkgolide B. Compared with the normal control group, the percentage of SOCS2 positive cells increased significantly ( P<0.01) and the percentage of Id2 positive cells decreased significantly ( P<0.01) in Ginkgolide B groups.ConclusionGinkgolide B can promote NSCs to differentiate into neuron and astrocyte, the percentage of astrocyte is increased with a dosage-dependent relationship with Ginkgolide B.

OBJECTIVE: To carry out prenatal diagnosis for a fetus with normal ultrasonographic finding at 20 weeks' gestation but a copy number variant(CNV) of 13q indicated by non-invasive prenatal test (NIPT). METHODS: Karyotyping analysis and chromosomal CNV assay were carried out on the amniotic fluid sample. Parental peripheral blood sample was collected for chromosomal analysis. Detailed fetal ultrasound scan was carried out to rule out structural abnormalities of the fetus. RESULTS: The fetus was detected with a heterozygous 10.14 Mb deletion at 13q21.1q21.32, which has originated from the phenotypically normal mother. No apparent karyotypic abnormality was detected in the fetus and its parents. No ultrasonic abnormality was found in the fetus. CONCLUSION Both the fetus and its mother have carried a heterozygous 10.14 Mb deletion at 13q21.1q21.32 and presented normal phenotypes.Combined with literature review, the segmental deletion was judged to be a benign variant.
Female ; Genetic Counseling ; Humans ; Karyotyping ; Pedigree ; Pregnancy ; Prenatal Diagnosis ; Ultrasonography, Prenatal

Objective To observe the effect of astragalus polysaccharide on motor function and pathology after spinal cord injury in rats. Methods Seventy adult Sprague-Dawley rats were selected as normal group (n=10), injury group (n=30) and treatment group (n=30), and the injury group and the treatment group were divided into 7 days, 14 days, 28 days subgroups. The injury group and the treatment group were modeled with Allen's mode at T10 (10 g×25 mm). The treatment group was injected with astragalus polysaccharide 10 mg/kg per day after injury. They were rated with Basso-Beattie-Bresnahan (BBB) scores 7 days, 14 days and 28 days after injury, while the morphology was observed with HE staining, Nylon body was observed with Nissl staining, and myelin sheath was observed with eriochrome cyanine staining. Results The BBB score was significantly higher in the treatment group than in the injury group at each time point (P<0.05). There was a large number of necrotic tissue in the injured cords and cystic cavity began to form 7 and 14 days after injury. Cystic cavity formed basically and surrounded with dense scar 28 days after injury. The necrosis and cystic cavity alleviated in the treatment group at each time point. Demyelination and myelin sheaths loose were found 7 days after injury, and aggravated with the time. There was a cystic cavity in trauma center 28 days after injury. The demyelination and myelin sheaths loose relieved at each time point in the treatment group. Nissl bodies began to coalesce 7 days after injury, and aggravated 14 days after injury, coalesced completely 28 days after injury. Nissl body coalesced alleviatively in the treatment group at each time point. Conclusion Astragalus polysaccharide may reduce the damage and promote the recovery of motor function after spinal cord injury in rats.